LNK

LNK Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of next-generation kinase inhibitors for autoimmune diseases and oncology. Headquartered in Suzhou, China, the company utilizes a proprietary structure-based drug design platform to create highly selective small molecule candidates with improved safety profiles. Its lead asset, LNK01001, is a selective JAK1 inhibitor currently in Phase 2 clinical trials for rheumatoid arthritis and atopic dermatitis. The pipeline also includes multi-kinase inhibitors and gut-restricted compounds designed to minimize systemic toxicity. LNK Therapeutics is backed by prominent life science investors and aims to deliver best-in-class therapies to global markets.